Your browser doesn't support javascript.
Environmental Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 During a COVID-19 Outbreak on the Diamond Princess Cruise Ship.
Yamagishi, Takuya; Ohnishi, Makoto; Matsunaga, Nobuaki; Kakimoto, Kensaku; Kamiya, Hajime; Okamoto, Kiyoko; Suzuki, Motoi; Gu, Yoshiaki; Sakaguchi, Mikiyo; Tajima, Taichi; Takaya, Saho; Ohmagari, Norio; Takeda, Makoto; Matsuyama, Shutoku; Shirato, Kazuya; Nao, Naganori; Hasegawa, Hideki; Kageyama, Tsutomu; Takayama, Ikuyo; Saito, Shinji; Wada, Koji; Fujita, Retsu; Saito, Hiroki; Okinaka, Keiji; Griffith, Mathew; Parry, Amy Elizabeth; Barnetson, Brenda; Leonard, James; Wakita, Takaji.
  • Yamagishi T; Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ohnishi M; National Institute of Infectious Diseases, Tokyo, Japan.
  • Matsunaga N; Antimicrobial Resistance Clinical Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kakimoto K; Field Epidemiology Training Program, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kamiya H; Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Okamoto K; Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki M; Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Gu Y; Antimicrobial Resistance Clinical Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sakaguchi M; Antimicrobial Resistance Clinical Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tajima T; Antimicrobial Resistance Clinical Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Takaya S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Takeda M; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Matsuyama S; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Shirato K; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Nao N; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Hasegawa H; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Kageyama T; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Takayama I; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Saito S; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Wada K; Graduate School of Public Health, International University of Health and Welfare, Chiba, Japan.
  • Fujita R; Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan.
  • Saito H; Department of Emergency and Critical Care Medicine, Yokohama City Seibu Hospital, St Marianna University School of Medicine, Yokohama, Japan.
  • Okinaka K; Division of General Internal Medicine, National Cancer Center Hospital East, Chiba, Japan.
  • Griffith M; Health Emergency Program, World Health Organization Western Pacific Regional Office, Manila, Philippines.
  • Parry AE; Health Emergency Program, World Health Organization Western Pacific Regional Office, Manila, Philippines.
  • Barnetson B; Department of Health Services, Princess Cruises, USA.
  • Leonard J; Department of Health Services, Princess Cruises, USA.
  • Wakita T; National Institute of Infectious Diseases, Tokyo, Japan.
J Infect Dis ; 222(7): 1098-1102, 2020 09 01.
Article in English | MEDLINE | ID: covidwho-661147
ABSTRACT
During a COVID-19 outbreak on the Diamond Princess cruise ship we sampled environmental surfaces after passengers and crew vacated cabins. SARS-CoV-2 RNA was detected in 58 of 601 samples (10%) from case cabins 1-17 days after cabins were vacated but not from noncase cabins. There was no difference in detection proportion between cabins of symptomatic (15%, 28/189; cycle quantification [Cq], 29.79-38.86) and asymptomatic cases (21%, 28/131; Cq, 26.21-38.99). No SARS-CoV-2 virus was isolated from any of the samples. Transmission risk of SARS-CoV-2 from symptomatic and asymptomatic patients may be similar and surfaces could be involved in transmission.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / RNA, Viral / Environmental Monitoring / Disease Outbreaks / Coronavirus Infections / Betacoronavirus Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: J Infect Dis Year: 2020 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / RNA, Viral / Environmental Monitoring / Disease Outbreaks / Coronavirus Infections / Betacoronavirus Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: J Infect Dis Year: 2020 Document Type: Article Affiliation country: Infdis